Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host conference call and webcast today at 5:00pm EDT / 2:00 PDT SAN DIEGO , May 13, 2019 (GLOBE NEWSWIRE)

Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , May 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it

Meeting to feature presentations on recent NRP-2-related discoveries by leading research experts in the field SAN DIEGO , April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel

SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a definitive agreement with The Federated

ATYR1923 shown to modulate inflammatory and fibrotic processes in multiple interstitial lung disease (ILD) animal models SAN DIEGO , April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based

Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March 2019 SAN DIEGO , March 25, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the

Abstract Describes Further Evidence that ATYR1923 Modulates Immune Cell Biology SAN DIEGO , March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it

Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline   aTyr eligible to receive up to $17 million in potential option fees SAN DIEGO , March 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery

SAN DIEGO , March 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing clinical